Selective targeting of point-mutated KRAS through artificial microRNAs

Citations of this article
Mendeley users who have this article in their library.


Mutated protein-coding genes drive the molecular pathogenesis of many diseases, including cancer. Specifically, mutated KRAS is a documented driver for malignant transformation, occurring early during the pathogenesis of cancers such as lung and pancreatic adenocarcinomas. Therapeutically, the indiscriminate targeting of wild-type and point-mutated transcripts represents an important limitation. Here, we leveraged on the design of miRNA-like artificial molecules (amiRNAs) to specifically target point-mutated genes, such as KRAS, without affecting their wild-type counterparts. Compared with an siRNA-like approach, the requirement of perfect complementarity of the microRNA seed region to a given target sequence in the microRNA/target model has proven to be a more efficient strategy, accomplishing the selective targeting of point-mutated KRAS in vitro and in vivo.

Author supplied keywords




Acunzo, M., Romano, G., Nigita, G., Veneziano, D., Fattore, L., Laganà, A., … Croce, C. M. (2017). Selective targeting of point-mutated KRAS through artificial microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 114(21), E4203–E4212.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free